{
    "document_id": "D-2024-3085",
    "LinkTitle": "D-2024-3085",
    "file_name": "D-2024-3085.pdf",
    "file_path": "/Users/JADEPOTTER5/Downloads/DMP-MT/processed_data/pdfs_new/org_pdfs/D-2024-3085.pdf",
    "metadata": {
        "title": "DeepHeartNet: a computational and functional characterization of the genetic architecture of non-syndromic congenital heart disease",
        "author": "N/A",
        "num_pages": 6
    },
    "content": {
        "full_text": "Plan Overview\nPlan Overview\nA Data Management Plan created using DMPonline.be\nTitle: \nTitle: \nDeepHeartNet: a computational and functional characterization of the genetic architecture of non-syndromic congenital heart\ndisease\nCreator:\nCreator:\nAlejandro Sifrim\nAffiliation: \nAffiliation: \nKU Leuven (KUL)\nTemplate: \nTemplate: \nKU Leuven BOF-IOF\nProject abstract:\nProject abstract:\nIsolated congenital heart disease (CHD) affects about 1 in 150 newborns and arises from both genetic and environmental factors.\nExtensive DNA sequencing by us and others revealed a significant burden of inherited rare variants in known and novel genes, but many\ngenes remain undiscovered due to lack of statistical power. Here, we will remedy this in 2 ways. Firstly, we will contribute to the largest\nwhole-exome sequencing CHD cohort to date. While more powered, many variants will likely still fail to achieve genome- wide\nsignificance. In a second stage, we will therefore build novel computational deep learning approaches for gene prioritization based on\nsingle-cell multi-omics datasets. Importantly, prioritized genes will also be validated, by implementing high-throughput gene perturbation\nin an in vitro cardiac progenitor differentiation model. Together, this project will improve the diagnostic yield in CHD patients, and thus\nameliorate genetic counselling for one of the leading causes of non-infectious child mortality.\nID: \nID: \n213910\nStart date: \nStart date: \n01-10-2024\nEnd date: \nEnd date: \n30-09-2028\nLast modified: \nLast modified: \n11-04-2025\nCreated using DMPonline.be. Last modiﬁed 11 April 2025\n1 of 6\nDeepHeartNet: a computational and functional characterization of the genetic architecture of non-\nDeepHeartNet: a computational and functional characterization of the genetic architecture of non-\nsyndromic congenital heart disease\nsyndromic congenital heart disease\nResearch Data Summary\nResearch Data Summary\nList and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For\nList and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For\neach dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know\neach dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know\nwhat data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type\nwhat data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type\nof the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data.\nof the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data.\nDataset name / ID\nDescription\nNew or\nreuse\nDigital or\nPhysical\ndata\nData Type\nFile format\nData\nvolume\nPhysical volume\n \n \nIndicate:\nN\nN\n(ew\ndata) or\nE\nE\n(xisting\ndata) \nIndicate: \nD\nD\n(igital)\nor\nP\nP\n(hysical)\nIndicate:\nA\nA\nudiovisual\nI\nI\nmages\nS\nS\nound\nN\nN\numerical\nT\nT\nextual\nM\nM\nodel\nSO\nSO\nftware\nOther\n(specify)\n \nIndicate:\n<1GB\n<100GB\n<1TB\n<5TB\n>5TB\nNA\n \n mus_MESP1+\nsingle-cell\nmulti-\nomics data\nin mus\nmusculus \nE\nD\nT\nFASTA/BAM/RDS\n<1TB\nVSC\n(stg_00077)/MANGO/External\nUSB HDD\nhuman_MESP1+_CROPSEQ\nCROPSeq\ndata in\nhuman cell\nline\nN\nD\nT\nFASTA/BAM/RDS\n<5TB\nVSC (stg_00077)/MANGO\nanalysis_code\nAnalysis\ncode\n(Python\nnotebooks)\nN\nD\nT\nPython\n<1GB\nGithub\nsample_metadata\nSample\nmetadata\nN\nD\nT\nTSV\n<1GB\nVSC (stg_00077)/MANGO\nai_models\nTrained AI\nmodels\nN\nD\nN\nPickled python\nobjects\n<1TB\nVSC (stg_00077)/MANGO\nhuman_sequencing_data\nHuman\nclinical\nWGS data\nN\nD\nT\nFASTA/BAM/VCF\n<10TB\nVSC (stg_00077)/MANGO\nIf you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per\nIf you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per\ndataset or data type:\ndataset or data type:\nQuestion not answered.\nAre there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If\nAre there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If\nso, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.\nso, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.\nYes, human subject data (Provide SMEC or EC approval number below)\nSequencing whole-genome sequencing data (\nEthical approval pending)\nEthical approval pending)\nCreated using DMPonline.be. Last modiﬁed 11 April 2025\n2 of 6\nWill you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven\nWill you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven\nor UZ Leuven privacy register number (G or S number).\nor UZ Leuven privacy register number (G or S number).\nYes (Provide PRET G-number or EC S-number below)\nS70151\nS70151\nDoes your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, …)?\nDoes your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, …)?\n If so, please comment per dataset or data type where appropriate. \n If so, please comment per dataset or data type where appropriate. \nNo\nDo existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material or Data transfer\nDo existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material or Data transfer\nagreements, Research collaboration agreements)? If so, please explain in the comment section to what data they relate and what\nagreements, Research collaboration agreements)? If so, please explain in the comment section to what data they relate and what\nrestrictions are in place.\nrestrictions are in place.\nNo\nAre there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you\nAre there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you\n(re)use? If so, please explain in the comment section to what data they relate and which restrictions will be asserted.\n(re)use? If so, please explain in the comment section to what data they relate and which restrictions will be asserted.\nNo\nDocumentation and Metadata\nDocumentation and Metadata\nClearly describe what approach will be followed to capture the accompanying information necessary to keep \nClearly describe what approach will be followed to capture the accompanying information necessary to keep \ndata\ndata\nunderstandable and usable\nunderstandable and usable\n, for yourself and others, now and in the future (e.g. in terms of documentation levels and types\n, for yourself and others, now and in the future (e.g. in terms of documentation levels and types\nrequired, procedures used, Electronic Lab Notebooks, README.txt files, codebook.tsv etc. where this information is recorded). \nrequired, procedures used, Electronic Lab Notebooks, README.txt files, codebook.tsv etc. where this information is recorded). \n- Sample metadata will be kept both in a metadata spreadsheet, as well as catalogued inside the MANGO metadata system.\n- Analysis code will be kept in Jupyter notebooks and version controlled using Git. Trained AI models will also be versioned and\nkept in MANGO with associated code repositories being referenced in the MANGO metadata.\nWill a metadata standard be used to make it easier to \nWill a metadata standard be used to make it easier to \nfind and reuse the data\nfind and reuse the data\n?  \n?  \nIf so, please specify which metadata standard will be used. \nIf so, please specify which metadata standard will be used. \nIf not, please specify which metadata will be created to make the data easier to find and reuse. \nIf not, please specify which metadata will be created to make the data easier to find and reuse. \nYes\nHuman phenotypes will be encoded using the Human Phenotype Ontology (HPO)\nSequencing instrument metadata outputted by the instruments will also be kept and catalogued\nCreated using DMPonline.be. Last modiﬁed 11 April 2025\n3 of 6\nData Storage & Back-up during the Research Project\nData Storage & Back-up during the Research Project\nWhere will the data be stored?\nWhere will the data be stored?\nManGO\nOther (specify below)\nWe will also keep active research data on our VSC volume (stg_00077) and cold archived in the FRIGO system.\nHow will the data be backed up?\nHow will the data be backed up?\nStandard back-up provided by KU Leuven ICTS for my storage solution\nIs there currently sufficient storage & backup capacity during the project? \nIs there currently sufficient storage & backup capacity during the project? \nIf no or insufficient storage or backup capacities are available, explain how this will be taken care of. \nIf no or insufficient storage or backup capacities are available, explain how this will be taken care of. \nYes\nHow will you ensure that the data are securely stored and not accessed or modified by unauthorized persons? \nHow will you ensure that the data are securely stored and not accessed or modified by unauthorized persons? \nOnly authorized persons will have access to the folder where the data will be stored (using the Linux/MANGO user permission\nsystems).\nWhat are the expected costs for data storage and backup during the research project? How will these costs be covered?\nWhat are the expected costs for data storage and backup during the research project? How will these costs be covered?\nWe envision <20TB will be generated/archived. At current costs of 30 Euro/TB/year this will amount to 2400 Euro (4 years of the\nproject). This will be funded by a VLIR infrastructure grant for data storage infrastructure obtained by the Leuven Institute of\nSingle-cell Omics and has also been taken into account in the funding budget.\nData Preservation after the end of the Research Project\nData Preservation after the end of the Research Project\nWhich data will be retained for 10 years (or longer, in agreement with other retention policies that are applicable) after the end of\nWhich data will be retained for 10 years (or longer, in agreement with other retention policies that are applicable) after the end of\nthe project? \nthe project? \nIn case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget\nIn case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget\nissues, institutional policies...).\nissues, institutional policies...).\nAll data will be preserved for 10 years according to KU Leuven RDM policy\nAll data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for\nhuman use and for clinical experiments on humans\nWhere will these data be archived (stored and curated for the long-term)? \nWhere will these data be archived (stored and curated for the long-term)? \nOther (specify below)\nWe will archive the data in cold storage solutions being worked out by KUL ICTS (FRIGO system). Clinical sequencing data will be\nCreated using DMPonline.be. Last modiﬁed 11 April 2025\n4 of 6\narchived as part of the Center of Human Genetics data repository for clinical sequencing data.\nWhat are the expected costs for data preservation during the expected retention period? How will these costs be covered?\nWhat are the expected costs for data preservation during the expected retention period? How will these costs be covered?\n20 Euro/TB/Year of cold storage x 20TB x 10 years = 4000 Euro. These costs will be covered by a VLIR infrastructure grant\n(PRISMO) for data storage which was obtained by the Leuven Institute of Single Cell Omics.\nData Sharing and Reuse\nData Sharing and Reuse\nWill the data (or part of the data) be made available for reuse after/during the project?  \nWill the data (or part of the data) be made available for reuse after/during the project?  \nPlease explain per dataset or data type which data will be made available.\nPlease explain per dataset or data type which data will be made available.\nYes, as open data\nYes, as restricted data (upon approval, or institutional access only)\nSingle-cell data will be made publicly available through public repositories such as the Gene Expression Omnibus (GEO).\nWGS sequencing data of patients will be made available through restricted access via a Data Access Committee through the\nEuropean Genome-Phenome Archive (EGA) repository.\nIf access is restricted, please specify who will be able to access the data and under what conditions. \nIf access is restricted, please specify who will be able to access the data and under what conditions. \nOnly credentialed researchers in relevant research fields will be able to access the clinical sequencing data after approval by\nthe DAC.\nAre there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party,\nAre there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party,\nlegal restrictions)? \nlegal restrictions)? \nPlease explain per dataset or data type where appropriate.\nPlease explain per dataset or data type where appropriate.\nYes, privacy aspects\nYes, ethical aspects\n- Clinical sequencing data is identifiable and as such data sharing needs to be appropriately consented and restricted according\nto the guidelines set by the ethical commission.\nWhere will the data be made available?  \nWhere will the data be made available?  \nIf already known, please provide a repository per dataset or data type.\nIf already known, please provide a repository per dataset or data type.\nOther data repository (specify below)\nSingle-cell data will be made publicly available through public repositories such as the Gene Expression Omnibus (GEO).\nWGS sequencing data of patients will be made available through restricted access via a Data Access Committee through the\nEuropean Genome-Phenome Archive (EGA) repository.\nWhen will the data be made available? \nWhen will the data be made available? \nUpon publication of research results\nCreated using DMPonline.be. Last modiﬁed 11 April 2025\n5 of 6\nWhich data usage licenses are you going to provide? \nWhich data usage licenses are you going to provide? \nIf none, please explain why. \nIf none, please explain why. \nData Transfer Agreement (restricted data)\nDo you intend to add a persistent identifier (PID) to your dataset(s), e.g. a DOI or accession number? If already available, please\nDo you intend to add a persistent identifier (PID) to your dataset(s), e.g. a DOI or accession number? If already available, please\nprovide it here. \nprovide it here. \n​​Yes, a PID will be added upon deposit in a data repository\nWhat are the expected costs for data sharing? How will these costs be covered?  \nWhat are the expected costs for data sharing? How will these costs be covered?  \nThe proposed public repositories provide this service free of charge.\nResponsibilities\nResponsibilities\nWho will manage data documentation and metadata during the research project? \nWho will manage data documentation and metadata during the research project? \nFatemeh Hoseinkhani (PhD Student)\nSaptarshi Chakrabarti (Data Engineer) \nWho will manage data storage and backup during the research project? \nWho will manage data storage and backup during the research project? \nSaptarshi Chakrabarti (Data Engineer) \nWho will manage data preservation and sharing? \nWho will manage data preservation and sharing? \nSaptarshi Chakrabarti (Data Engineer) \nWho will update and implement this DMP? \nWho will update and implement this DMP? \nFatemeh Hoseinkhani (PhD Student)\nSaptarshi Chakrabarti (Data Engineer) \nAlejandro Sifrim (PI)\nCreated using DMPonline.be. Last modiﬁed 11 April 2025\n6 of 6"
    },
    "clean_full_text": "Plan Overview Plan Overview A Data Management Plan created using DMPonline.be Title: Title: DeepHeartNet: a computational and functional characterization of the genetic architecture of non-syndromic congenital heart disease Creator: Creator: Alejandro Sifrim Affiliation: Affiliation: KU Leuven (KUL) Template: Template: KU Leuven BOF-IOF Project abstract: Project abstract: Isolated congenital heart disease (CHD) affects about 1 in 150 newborns and arises from both genetic and environmental factors. Extensive DNA sequencing by us and others revealed a significant burden of inherited rare variants in known and novel genes, but many genes remain undiscovered due to lack of statistical power. Here, we will remedy this in 2 ways. Firstly, we will contribute to the largest whole-exome sequencing CHD cohort to date. While more powered, many variants will likely still fail to achieve genome- wide significance. In a second stage, we will therefore build novel computational deep learning approaches for gene prioritization based on single-cell multi-omics datasets. Importantly, prioritized genes will also be validated, by implementing high-throughput gene perturbation in an in vitro cardiac progenitor differentiation model. Together, this project will improve the diagnostic yield in CHD patients, and thus ameliorate genetic counselling for one of the leading causes of non-infectious child mortality. ID: ID: 213910 Start date: Start date: 01-10-2024 End date: End date: 30-09-2028 Last modified: Last modified: 11-04-2025 Created using DMPonline.be. Last modiﬁed 11 April 2025 1 of 6 DeepHeartNet: a computational and functional characterization of the genetic architecture of non- DeepHeartNet: a computational and functional characterization of the genetic architecture of non- syndromic congenital heart disease syndromic congenital heart disease Research Data Summary Research Data Summary List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data. of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data. Dataset name / ID Description New or reuse Digital or Physical data Data Type File format Data volume Physical volume Indicate: N N (ew data) or E E (xisting data) Indicate: D D (igital) or P P (hysical) Indicate: A A udiovisual I I mages S S ound N N umerical T T extual M M odel SO SO ftware Other (specify) Indicate: <1GB <100GB <1TB <5TB >5TB NA mus_MESP1+ single-cell multi- omics data in mus musculus E D T FASTA/BAM/RDS <1TB VSC (stg_00077)/MANGO/External USB HDD human_MESP1+_CROPSEQ CROPSeq data in human cell line N D T FASTA/BAM/RDS <5TB VSC (stg_00077)/MANGO analysis_code Analysis code (Python notebooks) N D T Python <1GB Github sample_metadata Sample metadata N D T TSV <1GB VSC (stg_00077)/MANGO ai_models Trained AI models N D N Pickled python objects <1TB VSC (stg_00077)/MANGO human_sequencing_data Human clinical WGS data N D T FASTA/BAM/VCF <10TB VSC (stg_00077)/MANGO If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type: dataset or data type: Question not answered. Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number. so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number. Yes, human subject data (Provide SMEC or EC approval number below) Sequencing whole-genome sequencing data ( Ethical approval pending) Ethical approval pending) Created using DMPonline.be. Last modiﬁed 11 April 2025 2 of 6 Will you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven Will you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number). or UZ Leuven privacy register number (G or S number). Yes (Provide PRET G-number or EC S-number below) S70151 S70151 Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, …)? Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, …)? If so, please comment per dataset or data type where appropriate. If so, please comment per dataset or data type where appropriate. No Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material or Data transfer Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material or Data transfer agreements, Research collaboration agreements)? If so, please explain in the comment section to what data they relate and what agreements, Research collaboration agreements)? If so, please explain in the comment section to what data they relate and what restrictions are in place. restrictions are in place. No Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you (re)use? If so, please explain in the comment section to what data they relate and which restrictions will be asserted. (re)use? If so, please explain in the comment section to what data they relate and which restrictions will be asserted. No Documentation and Metadata Documentation and Metadata Clearly describe what approach will be followed to capture the accompanying information necessary to keep Clearly describe what approach will be followed to capture the accompanying information necessary to keep data data understandable and usable understandable and usable , for yourself and others, now and in the future (e.g. in terms of documentation levels and types , for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, codebook.tsv etc. where this information is recorded). required, procedures used, Electronic Lab Notebooks, README.txt files, codebook.tsv etc. where this information is recorded). - Sample metadata will be kept both in a metadata spreadsheet, as well as catalogued inside the MANGO metadata system. - Analysis code will be kept in Jupyter notebooks and version controlled using Git. Trained AI models will also be versioned and kept in MANGO with associated code repositories being referenced in the MANGO metadata. Will a metadata standard be used to make it easier to Will a metadata standard be used to make it easier to find and reuse the data find and reuse the data ? ? If so, please specify which metadata standard will be used. If so, please specify which metadata standard will be used. If not, please specify which metadata will be created to make the data easier to find and reuse. If not, please specify which metadata will be created to make the data easier to find and reuse. Yes Human phenotypes will be encoded using the Human Phenotype Ontology (HPO) Sequencing instrument metadata outputted by the instruments will also be kept and catalogued Created using DMPonline.be. Last modiﬁed 11 April 2025 3 of 6 Data Storage & Back-up during the Research Project Data Storage & Back-up during the Research Project Where will the data be stored? Where will the data be stored? ManGO Other (specify below) We will also keep active research data on our VSC volume (stg_00077) and cold archived in the FRIGO system. How will the data be backed up? How will the data be backed up? Standard back-up provided by KU Leuven ICTS for my storage solution Is there currently sufficient storage & backup capacity during the project? Is there currently sufficient storage & backup capacity during the project? If no or insufficient storage or backup capacities are available, explain how this will be taken care of. If no or insufficient storage or backup capacities are available, explain how this will be taken care of. Yes How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons? How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons? Only authorized persons will have access to the folder where the data will be stored (using the Linux/MANGO user permission systems). What are the expected costs for data storage and backup during the research project? How will these costs be covered? What are the expected costs for data storage and backup during the research project? How will these costs be covered? We envision <20TB will be generated/archived. At current costs of 30 Euro/TB/year this will amount to 2400 Euro (4 years of the project). This will be funded by a VLIR infrastructure grant for data storage infrastructure obtained by the Leuven Institute of Single-cell Omics and has also been taken into account in the funding budget. Data Preservation after the end of the Research Project Data Preservation after the end of the Research Project Which data will be retained for 10 years (or longer, in agreement with other retention policies that are applicable) after the end of Which data will be retained for 10 years (or longer, in agreement with other retention policies that are applicable) after the end of the project? the project? In case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget In case some data cannot be preserved, clearly state the reasons for this (e.g. legal or contractual restrictions, storage/budget issues, institutional policies...). issues, institutional policies...). All data will be preserved for 10 years according to KU Leuven RDM policy All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans Where will these data be archived (stored and curated for the long-term)? Where will these data be archived (stored and curated for the long-term)? Other (specify below) We will archive the data in cold storage solutions being worked out by KUL ICTS (FRIGO system). Clinical sequencing data will be Created using DMPonline.be. Last modiﬁed 11 April 2025 4 of 6 archived as part of the Center of Human Genetics data repository for clinical sequencing data. What are the expected costs for data preservation during the expected retention period? How will these costs be covered? What are the expected costs for data preservation during the expected retention period? How will these costs be covered? 20 Euro/TB/Year of cold storage x 20TB x 10 years = 4000 Euro. These costs will be covered by a VLIR infrastructure grant (PRISMO) for data storage which was obtained by the Leuven Institute of Single Cell Omics. Data Sharing and Reuse Data Sharing and Reuse Will the data (or part of the data) be made available for reuse after/during the project? Will the data (or part of the data) be made available for reuse after/during the project? Please explain per dataset or data type which data will be made available. Please explain per dataset or data type which data will be made available. Yes, as open data Yes, as restricted data (upon approval, or institutional access only) Single-cell data will be made publicly available through public repositories such as the Gene Expression Omnibus (GEO). WGS sequencing data of patients will be made available through restricted access via a Data Access Committee through the European Genome-Phenome Archive (EGA) repository. If access is restricted, please specify who will be able to access the data and under what conditions. If access is restricted, please specify who will be able to access the data and under what conditions. Only credentialed researchers in relevant research fields will be able to access the clinical sequencing data after approval by the DAC. Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)? legal restrictions)? Please explain per dataset or data type where appropriate. Please explain per dataset or data type where appropriate. Yes, privacy aspects Yes, ethical aspects - Clinical sequencing data is identifiable and as such data sharing needs to be appropriately consented and restricted according to the guidelines set by the ethical commission. Where will the data be made available? Where will the data be made available? If already known, please provide a repository per dataset or data type. If already known, please provide a repository per dataset or data type. Other data repository (specify below) Single-cell data will be made publicly available through public repositories such as the Gene Expression Omnibus (GEO). WGS sequencing data of patients will be made available through restricted access via a Data Access Committee through the European Genome-Phenome Archive (EGA) repository. When will the data be made available? When will the data be made available? Upon publication of research results Created using DMPonline.be. Last modiﬁed 11 April 2025 5 of 6 Which data usage licenses are you going to provide? Which data usage licenses are you going to provide? If none, please explain why. If none, please explain why. Data Transfer Agreement (restricted data) Do you intend to add a persistent identifier (PID) to your dataset(s), e.g. a DOI or accession number? If already available, please Do you intend to add a persistent identifier (PID) to your dataset(s), e.g. a DOI or accession number? If already available, please provide it here. provide it here. ​​Yes, a PID will be added upon deposit in a data repository What are the expected costs for data sharing? How will these costs be covered? What are the expected costs for data sharing? How will these costs be covered? The proposed public repositories provide this service free of charge. Responsibilities Responsibilities Who will manage data documentation and metadata during the research project? Who will manage data documentation and metadata during the research project? Fatemeh Hoseinkhani (PhD Student) Saptarshi Chakrabarti (Data Engineer) Who will manage data storage and backup during the research project? Who will manage data storage and backup during the research project? Saptarshi Chakrabarti (Data Engineer) Who will manage data preservation and sharing? Who will manage data preservation and sharing? Saptarshi Chakrabarti (Data Engineer) Who will update and implement this DMP? Who will update and implement this DMP? Fatemeh Hoseinkhani (PhD Student) Saptarshi Chakrabarti (Data Engineer) Alejandro Sifrim (PI) Created using DMPonline.be. Last modiﬁed 11 April 2025 6 of 6"
}